跳至主要内容
临床试验/NCT01307982
NCT01307982已完成不适用

Comparative Anti-Reflux Procedures in Neurologically Impaired Children

University of Utah2 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2011年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
3
试验地点
2
主要终点
GERD-related hospitalization and ED visits

研究概览

简要总结

This trial is a randomized controlled trial of two standard anti-reflux procedures, Nissen fundoplication versus gastrojejunal feeding tubes (GJ tubes), in children and adolescents with functional and intellectual impairment who have gastrostomy feeding tubes and medically refractory or severe gastroesophageal reflux disease (GERD). This is a pilot study to establish feasibility before initiating a multi-centered study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • patient is between 6 months and 18 years of age; AND
  • patient has functional impairment classified by either gross motor functional classification of 3, 4 or 5 OR impaired function in walking, crawling/standing, rolling/sitting, arm use, hand use, ability to hold head up; AND
  • patient has a gastrostomy; AND
  • patient has intolerance of feedings or other complications attributed to GERD as defined below; AND
  • patient has a positive GERD diagnostic evaluation as define below:
  • GERD diagnostic evaluation will include the following investigations;
  • endoscopy and biopsy for visual assessment and histology of the esophageal mucosa
  • pH study and/or multichannel intraluminal impedance (MII) probe to detect and quantify gastroesophageal reflux
  • GER demonstrated by:
  • Reflux Esophagitis: Endoscopic appearance of mucosal breaks in the distal esophagus with or without pathologist diagnosis based on one or more biopsy histologic features of: inflammatory cellular infiltrate, basal cell hyperplasia, elongation of the vascular papillae AND no infectious microorganisms and < 15 eosinophils per high power field; OR
  • pH OR pH/multichannel intraluminal impedance(MII) probe evidence of pathologic GER:
  • pH probe: acid reflux index > 7 % OR
  • pH/MII reflux symptom-associated acid or non-acid volume associated reflux events;
  • Upper GI will only be used to determine normal anatomy; AND
  • patient has either medically refractory GERD or severe GERD as defined below:
  • Medically refractory GERD - GERD that has not responded to 12 weeks of treatment with a proton pump inhibitor (PPI) (and verified gastric pH > 4) and/or trial of continuous intragastric feedings and has one of the following complications:
  • Esophagitis: Endoscopic appearance of mucosal breaks in the distal esophagus with or without pathologist diagnosis based on one or more biopsy histologic features of: inflammatory cellular infiltrate, basal cell hyperplasia, elongation of the vascular papillae
  • Failure to thrive: diminishing weight percentile for age or weight for age z-score sustained over 6 months.
  • Pneumonia consistent with aspiration,
  • Acute life threatening event,
  • Severe GERD - at least one severe complication of GERD and patient cannot safely tolerate a trial of medical management due to one of the following life-threatening complications:
  • aspiration pneumonia,
  • acute life threatening event (ALTE),
  • complete loss of airway protection (absent cough/gag) AND,
  • Upper GI barium contrast study for anatomy; AND
  • Barium pharyngeal swallow study or modified barium swallow study or Flexible Endoscopic Evaluation of Swallowing (FEES) in past year; AND
  • the parent or legal guardian speaks English or Spanish (the only two languages in which the instruments are standardized)

排除标准

  • Upper GI findings that would mandate a fundoplication including: hiatal hernia, esophageal stricture, Barret's esophagus; OR
  • Upper GI findings show uncorrected distal gastrointestinal obstruction including: gastric outlet obstruction, duodenal obstruction, malrotation; OR
  • Upper GI demonstrates structural foregut abnormalities that preclude a fundoplication including: microgastria, short esophagus, high anesthetic risk; OR
  • Diagnosis or history of congenital diaphragmatic hernia, esophageal atresia, chronic intestinal pseudoobstruction; OR
  • Endoscopy and biopsy demonstrates esophagitis from causes other than GER including: eosinophilic esophagitis, candida esophagitis, viral esophagitis); OR
  • Rapidly changing or indeterminate neurological including either a deteriorating neurological condition such as rapid loss of developmental milestones or improving, such as rapid recovery following severe neurological insult; OR
  • Patient has unacceptable general anesthetic risk; OR
  • A previous Nissen fundoplication; OR
  • Feeds delivered by GJ/NJ at the time of enrollment occurring for greater than 3 months.

结局指标

主要结局

GERD-related hospitalization and ED visits

时间窗: 12 months

Parental interviews and chart reviews will be used to record all health care encounters. Each encounter will be classified as either GERD-related or not. GERD-related hospitalizations and ED visits will be further classified as; diagnostic testing, procedural problems, likely aspiration pneumonia (AP or bacterial pneumonia), respiratory distress of other etiology, or death from any cause.

次要结局

  • Health Related Quality of Life(12 months)
  • Total length of stay(12 months)
  • Complications from treatment(12 months)
  • Complications from failure of treatment(12 months)
  • Mortality(12 months)
  • Costs related to hospital, ED, outpatient, and home-health care(12 months)
  • Nutritional outcomes(12 months)
  • Other outpatient health care(12 months)
  • Symptom control(12 months)
  • Parental Goals of either treatment for GERD(12 months)
  • Physician Goals of either treatment for GERD(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Raj Srivastava

Dr. Raj Srivastava, MD, MPH

University of Utah

研究点 (2)

Loading locations...

相似试验

Comparative Anti-Reflux Procedures in Neurologically... | 临床试验